Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.40 |
| ▸ | RORC | P51449 | 4/20 | 0.38 |
| ▸ | BCL9 | O00512 | 1/20 | 0.37 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL493509 | 0.94 | GAA (0.42) | GAAHPGDKMT2ACACNA1BRORC | |
| SCHEMBL493977 | 0.94 | CCR2 (0.43) | GAAHPGDKMT2ACACNA1BRORC | |
| SCHEMBL493443 | 0.90 | KMT2A (0.44) | GAAHPGDKMT2AL3MBTL1MEN1 | |
| SCHEMBL492793 | 0.88 | GAA (0.43) | GAAHPGDKMT2ACACNA1BRORC | |
| SCHEMBL493254 | 0.88 | GAA (0.44) | GAAHPGDKMT2ACACNA1BRORC | |
| SCHEMBL493352 | 0.87 | KMT2A (0.41) | KMT2AMEN1 | |
| SCHEMBL492813 | 0.87 | KMT2A (0.41) | KMT2AMEN1 | |
| SCHEMBL492780 | 0.87 | GAA (0.41) | GAAHPGDKMT2ACACNA1BRORC | |
| SCHEMBL493124 | 0.87 | MEN1 (0.41) | GAAKMT2AMEN1 | |
| SCHEMBL493433 | 0.86 | KMT2A (0.41) | GAAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | claimed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | claimed |
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| EP-2139851-A2 | SUBSTITUTED AMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2010-01-06 | — | — | EP | disclosed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
| WO-2008131946-A2 | SUBSTITUTED AMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306084-A1 | Substituted Amide Compounds | OPRK1, NAA50, ACMSD | GAA 445/4885HPGD 213/4885KMT2A 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.